The β-Nicotinamide mononucleotide Diaries
;In vivo: MK-4827 is well tolerated in vivo and demonstrates efficacy as one agent inside a xenograft model of BRCA-1 deficient cancer [1]. On top of that, MK-4827 strongly enhances the result of radiation on several different human tumor xenografts, the two p53 wild sort and p53 mutant. The improvement of radiation response is observed in clinical